Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jul '25 Jul 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	2015 - 2019
Net Income	-11.12	-12.55	-9.81	-13.6	-12.95	-10.02	Upgrade
Depreciation & Amortization	0.04	0.04	0.05	0.04	0.06	0.09	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-	-0.01	0.15	Upgrade
Stock-Based Compensation	3.9	4.8	4.74	6.75	8.06	4.14	Upgrade
Other Operating Activities	-0.2	-0.14	-0.12	-0.18	-0.17	-0.07	Upgrade
Change in Accounts Receivable	0.41	0.1	-0.22	-0.03	-	0.06	Upgrade
Change in Accounts Payable	-0.03	0.32	-0.06	0.13	-0.1	-0.35	Upgrade
Change in Other Net Operating Assets	0.14	0.11	-0.78	0.39	0.17	-0.17	Upgrade
Operating Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.18	Upgrade
Capital Expenditures	-	-	-	-	-	-0.02	Upgrade
Sale of Property, Plant & Equipment	-	-	-	-	0.04	-	Upgrade
Investment in Securities	5.08	4.28	-5.6	-10.73	-3.96	-0.29	Upgrade
Investing Cash Flow	5.08	4.28	-5.6	-10.73	-3.92	-0.31	Upgrade
Issuance of Common Stock	2.03	3.42	0.37	0.45	31.57	9.41	Upgrade
Repurchase of Common Stock	-0.01	-0.01	-	-	-	-	Upgrade
Other Financing Activities	0.02	-	-	-	-	-	Upgrade
Financing Cash Flow	2.04	3.42	0.37	0.45	31.57	9.41	Upgrade
Net Cash Flow	0.27	0.36	-11.45	-16.77	22.71	2.93	Upgrade
Free Cash Flow	-6.85	-7.34	-6.21	-6.49	-4.94	-6.19	Upgrade
Free Cash Flow Margin	-	-	-2956.67%	-	-964.45%	-	Upgrade
Free Cash Flow Per Share	-0.21	-0.23	-0.20	-0.21	-0.17	-0.28	Upgrade
Levered Free Cash Flow	-2.76	-3	-3.02	-1.26	0.04	-2.64	Upgrade
Unlevered Free Cash Flow	-2.76	-3	-3.02	-1.26	0.04	-2.64	Upgrade
Change in Working Capital	0.53	0.53	-1.06	0.49	0.08	-0.46	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.